Get the Stockscreener App
84.15
5.56%
4.43
After Hours:
84.02
-0.13
-0.15%
Edwards Lifesciences Corp stock is traded at $84.15, with a volume of 11.80M.
It is up +5.56% in the last 24 hours and up +3.01% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$79.72
Open:
$82.5
24h Volume:
11.80M
Relative Volume:
2.39
Market Cap:
$48.52B
Revenue:
$6.07B
Net Income/Loss:
$1.06B
P/E Ratio:
46.59
EPS:
1.8063
Net Cash Flow:
$1.34B
1W Performance:
+3.90%
1M Performance:
+3.01%
6M Performance:
+10.58%
1Y Performance:
+12.01%
1-Day Range:
$82.12
$84.74
1-Week Range:
$79.19
$84.74
52-Week Range:
$72.30
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
84.15 | 45.96B | 6.07B | 1.06B | 1.34B | 1.8063 |
ABT
Abbott Laboratories
|
91.13 | 160.70B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
327.51 | 126.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
83.32 | 107.58B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.07 | 97.63B | 20.62B | 3.56B | 3.66B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
A Look at Edwards Lifesciences Corp (EW) After 5.6% Gain -- GF V - GuruFocus
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
Edwards Lifesciences Stock Surges On Heart Valve Devices Growth - Benzinga
Edwards raises 2026 guidance on strong TAVR performance - BioWorld News
Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises - Quiver Quantitative
TD Cowen reiterates Edwards Lifesciences stock Buy rating on strong Q1 results - Investing.com
Edwards Lifesciences raises FY26 guidance following strong Q1 - Medical Device Network
Bernstein SocGen raises Edwards Lifesciences stock price target to $96 - Investing.com
Stifel reiterates Edwards Lifesciences stock rating on strong Q1 beat - Investing.com
Edwards Lifesciences (NYSE:EW) Given New $87.00 Price Target at Robert W. Baird - MarketBeat
Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at BTIG Research - MarketBeat
OLD National Bancorp IN Sells 16,066 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Bernstein Adjusts PT on Edwards Lifesciences to $96 From $95, Maintains Market Perform Rating - marketscreener.com
Teacher Retirement System of Texas Has $23.75 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Canaccord Genuity Adjusts PT on Edwards Lifesciences to $85 From $87, Maintains Hold Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Edwards Lifesciences to $98 From $97, Maintains Buy Rating - marketscreener.com
BTIG raises Edwards Lifesciences stock price target on strong Q1 beat - Investing.com Australia
BTIG raises Edwards Lifesciences stock price target on strong Q1 beat By Investing.com - Investing.com South Africa
Canaccord cuts Edwards Lifesciences stock price target on valuation - Investing.com
Barclays raises Edwards Lifesciences stock price target on EBITDA outlook - Investing.com
Truist raises Edwards Lifesciences stock price target on TAVR growth By Investing.com - Investing.com Canada
Edwards Lifesciences Corp (EW) Q1 2026 Earnings Call Highlights: - GuruFocus
Edwards Lifesciences Q1 Earnings Call Highlights - MarketBeat
Edwards Lifesciences reports Q1 EPS 78c, consensus 73c - TipRanks
Edwards Lifesciences (EW) Raises FY26 Sales Growth Guidance - GuruFocus
Earnings call transcript: Edwards Lifesciences Q1 2026 beats expectations By Investing.com - Investing.com Australia
Transcript: Edwards Lifesciences Q1 2026 Earnings Conference Call - Benzinga
Is Edwards Lifesciences (EW) Still 13.6% Undervalued After Q1 20 - GuruFocus
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Q1 2026 Edwards Lifesciences Corp Earnings Call Transcript - GuruFocus
Edwards Lifesciences (NYSE:EW) Releases Q2 2026 Earnings Guidance - MarketBeat
Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Edwards Lifesciences options imply 5.2% move in share price post-earnings - TipRanks
Edwards Lifesciences (EW) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
Edwards Lifesciences shares rise 4% as guidance raised following Q1 earnings beat - Investing.com Canada
Edwards Lifesciences shares rise 4% as guidance raised following Q1 earnings beat By Investing.com - Investing.com India
Edwards Lifesciences Q1 Earnings, Revenue Rise - marketscreener.com
Edwards Lifesciences (NYSE:EW) Releases Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Edwards Lifesciences reports Q1 revenue $1.65B, raises 2026 sales and adjusted EPS guidance - TradingView
Stronger Q1 boosts 2026 outlook for Edwards Lifesciences (NYSE: EW) - Stock Titan
Heart-valve demand drives Edwards to raise 2026 forecast - Stock Titan
Edwards Lifesciences Reports First Quarter Results - ChartMill
Edwards Lifesciences earnings on deck as TAVR share gains loom By Investing.com - Investing.com South Africa
Edwards Lifesciences earnings on deck as TAVR share gains loom - Investing.com
Edwards Lifesciences Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape - Markets Mojo
Universal Beteiligungs und Servicegesellschaft mbH Acquires 21,165 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Zurcher Kantonalbank Zurich Cantonalbank Buys 23,305 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect - Yahoo Finance
TriaGen Wealth Management LLC Invests $4.55 Million in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):